Avastin, the blockbuster drug that just lost approval for treating breast cancer, now looks disappointing against ovarian cancer, too. Two studies found it did not improve survival for most of these patients and kept their disease from worsening for only a few months, with more side effects.
Related posts:
Any Exercise Benefits Kids' Heart Health: Study
Certain Antipsychotics Up Risk of Death for Patients With Dementia: Study
Exercise, vitamin D may prevent falls: guidelines
Intel exploring ways to help Stephen Hawking speak
US reviews research risks amid bird-flu debate
Watch: Man's Best Asthma Preventer?